Not a good buy right now for an impatient investor: price (~117.18) is extended above near-term resistance (R2 ~116.47) while fundamentals just weakened (EPS miss + FY26 guide down).
Risk/reward looks skewed lower near-term: short-term technicals are overbought (RSI6 71.6) and analyst targets cluster below the current price (109–115).
Event-driven bounce from GOJO (Purell) acquisition and “cost savings later in FY” is real, but the market is likely to fade it given softer demand/price-mix and reduced outlook.
Trend/momentum: MACD histogram +0.269 and expanding suggests bullish momentum, but it’s late-stage/extended.
Overbought/extension: RSI_6 at ~71.6 indicates short-term overbought conditions (prone to pullbacks rather than fresh entries).
Levels: Price ~117.18 is above R2 (116.47). Next key area is to watch for a failed hold above ~116.5; downside magnet is pivot ~111.93, then S1 ~109.12.
Moving averages: converging MAs suggest consolidation risk after the recent push.
Pattern-based forward look: Similar-pattern stats imply modest next-week upside (+3.0%) but negative next-month bias (-2.7%), reinforcing “not a chase.”
Options Data
Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Sentiment tilt: Put/Call < 1 on both OI (0.58) and volume (0.57) = more call interest than puts (mildly bullish positioning).
Activity: Today’s options volume 5,372 is elevated (148.6% of 30-day avg), suggesting heightened event-driven trading.
Volatility: 30D IV ~29.33 vs historical vol ~21.12; IV percentile 76 = options are relatively expensive (market pricing higher uncertainty).
Takeaway: Options skew is bullish, but elevated IV after earnings/guidance changes often precedes mean reversion in price rather than a clean continuation.
Technical Summary
Sell
6
Buy
10
Positive Catalysts
Higher cost savings expected in the back half of the fiscal year.
Neutral/Negative Catalysts
Sales softness: Q2 net sales down ~1% YoY (inventory drawdowns and reduced demand signals).
Financial Performance
Latest quarter: 2026/Q2.
Revenue: $1.673B, down ~0.77% YoY (flat-to-down top line).
Net income: $157M, down ~18.65% YoY (meaningful earnings compression).
EPS: $1.29, down ~16.77% YoY (growth trend negative).
Gross margin: 43.45%, down ~0.46% YoY (slight deterioration).
Overall: mixed operational progress, but growth and profitability trends weakened in the latest quarter and guidance was reduced—bad setup for chasing at elevated technical levels.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: mostly Hold/Neutral/Equal Weight; targets were generally adjusted modestly upward into ~114–115 by Citi/Deutsche/Wells, but with notable bearish offsets (Goldman Sell with $94; Barclays Underweight ~$109).
Net effect: Wall Street is not broadly bullish—consensus tone is cautious/neutral, focused on weak consumer/staples volume, muted pricing, and lingering operational headwinds.
Pros (Street view): portfolio improvement via GOJO, distribution recovery progress, defensive characteristics.
Cons (Street view): lackluster sales outlook, margin/price-mix pressure, and valuation/target gap (current price above many targets).
Influential/political activity: no recent congress trading data available; hedge funds/insiders show neutral recent trend.
Wall Street analysts forecast CLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLX is 118.09 USD with a low forecast of 94 USD and a high forecast of 152 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast CLX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLX is 118.09 USD with a low forecast of 94 USD and a high forecast of 152 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
9 Hold
2 Sell
Hold
Current: 117.610
Low
94
Averages
118.09
High
152
Current: 117.610
Low
94
Averages
118.09
High
152
JPMorgan
Andrea Teixeira
Neutral
maintain
$114 -> $117
AI Analysis
2026-02-04
New
Reason
JPMorgan
Andrea Teixeira
Price Target
$114 -> $117
AI Analysis
2026-02-04
New
maintain
Neutral
Reason
JPMorgan analyst Andrea Teixeira raised the firm's price target on Clorox to $117 from $114 and keeps a Neutral rating on the shares. The firm updated the company's model post the fiscal Q2 report.
RBC Capital
Sector Perform
downgrade
$142 -> $132
2026-02-04
New
Reason
RBC Capital
Price Target
$142 -> $132
2026-02-04
New
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on Clorox to $132 from $142 and keeps a Sector Perform rating on the shares. The company reported a stronger-than-expected topline with help from shipment timing, but higher costs pressured margins leading to an EPS miss, the analyst tells investors in a research note.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CLX
